Zacks Investment Research restated their sell rating on shares of Xencor (NASDAQ:XNCR) in a report released on Saturday.
According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “
A number of other equities analysts also recently commented on XNCR. ValuEngine downgraded shares of Xencor from a hold rating to a sell rating in a report on Monday, October 23rd. BidaskClub downgraded shares of Xencor from a sell rating to a strong sell rating in a report on Friday, December 15th. Piper Jaffray Companies reiterated a buy rating and issued a $35.00 target price on shares of Xencor in a report on Sunday, November 12th. Cantor Fitzgerald assumed coverage on shares of Xencor in a report on Wednesday, November 29th. They issued an overweight rating and a $33.00 target price for the company. Finally, Canaccord Genuity set a $36.00 target price on shares of Xencor and gave the stock a buy rating in a report on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus target price of $30.80.
Xencor (NASDAQ:XNCR) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.04). Xencor had a negative return on equity of 15.26% and a negative net margin of 148.29%. sell-side analysts forecast that Xencor will post -1.1 EPS for the current fiscal year.
In related news, major shareholder John S. Stafford III acquired 24,653 shares of the business’s stock in a transaction dated Wednesday, October 25th. The shares were purchased at an average price of $20.01 per share, for a total transaction of $493,306.53. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder John S. Stafford III acquired 50,000 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were bought at an average price of $19.58 per share, for a total transaction of $979,000.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 278,535 shares of company stock worth $5,526,936. Corporate insiders own 4.14% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Great West Life Assurance Co. Can increased its holdings in shares of Xencor by 158.9% during the third quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 4,005 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Xencor by 62.6% during the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 3,252 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Xencor by 4.5% during the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 385 shares in the last quarter. Principal Financial Group Inc. acquired a new position in shares of Xencor during the third quarter valued at about $201,000. Finally, Citadel Advisors LLC acquired a new position in shares of Xencor during the second quarter valued at about $224,000. Hedge funds and other institutional investors own 77.50% of the company’s stock.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.